NanoenTek,Inc.
Financials
Valuation Metrics
NanoenTek,Inc.'s Market Cap is ₩1588B. At end of 2025 it was ₩2286B. Ranked #995 of 2,421 in KR market (top 41%), #498 of 1,640 on KOSDAQ (top 30%), #111 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 48%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 158.85B KRW | KR#995/2,421 Sec#111/231 |
| Revenue | 44.19B KRW | KR#1,861/2,421 Sec#131/231 |
| Net Income | 5.86B KRW | KR#1,144/2,421 Sec#72/231 |
| Total Assets | 102.20B KRW | KR#1,757/2,421 Sec#140/231 |
| Net Assets | 94.06B KRW | KR#1,466/2,421 Sec#118/231 |
| Employees | 138 | KR#1,388/2,421 Sec#112/231 |
| Value | ||
| P/E | 27.10x | KR#1,280/2,421 Sec#77/231 |
| P/B | 1.69x | KR#1,836/2,421 Sec#132/231 |
| PEG | 0.12x | KR#440/2,421 Sec#21/231 |
| P/S | 3.59x | KR#2,053/2,421 Sec#131/231 |
| FCF Yield | 1.49% | KR#1,098/2,421 Sec#77/231 |
| Profitability | ||
| ROE | 6.23% | KR#963/2,421 Sec#68/231 |
| ROA | 5.74% | KR#657/2,421 Sec#54/231 |
| Op. Margin | 3.80% | KR#1,122/2,421 Sec#80/231 |
| Revenue Growth | 29.61% | KR#398/2,421 Sec#41/231 |
| Earnings Growth | 231.25% | KR#219/2,421 Sec#11/231 |
| Financial Health | ||
| Debt Ratio | 8.65% | KR#110/2,421 Sec#22/231 |
| FCF | 2.37B KRW | KR#1,058/2,421 Sec#74/231 |
| Cash | 12.26B KRW | KR#1,571/2,421 Sec#130/231 |
| Current Ratio | 11.28x | KR#82/2,421 Sec#20/231 |
| Performance | ||
| 1Y Return | 19.14% | KR#448/2,421 Sec#30/231 |
| 1M Return | 13.47% | KR#370/2,421 Sec#21/231 |
| From 52W High | -55.59% | KR#1,681/2,421 Sec#127/231 |
| 1Y MDD | -57.30% | KR#1,328/2,421 Sec#109/231 |
| Trading | ||
| Volume | 180,697 shares | KR#520/2,421 Sec#35/231 |
| Trading Value | 761.6M KRW | KR#802/2,421 Sec#82/231 |
| Foreign Own. | 1.36% | KR#1,887/2,421 Sec#185/231 |
| Per Share | ||
| EPS | 154 KRW | KR#1,356/2,421 Sec#89/231 |
| BPS | 2,469 KRW | KR#1,962/2,421 Sec#155/231 |
Company Info
NanoEnTek, established in 1987 as an information security business and rebranded in 2006, is headquartered in Guro-gu, Seoul. The company, slated to become a subsidiary of AAI Healthcare in 2025, specializes in Lab-on-a-chip based in-vitro diagnostic devices and immunodiagnostic systems. Its FREND System has received FDA approval and is stably supplied in North America. Utilizing Bio-MEMS and microfluidic technology, NanoEnTek conducts precise clinical tests, holding 108 registrations and expanding its business globally.